Article

Prognostic relevance of Neutrophil to Lymphocyte Ratio (NLR) in luminal breast cancer: a retrospective analysis in the neoadjuvant setting.

Antonino Grassadonia1,*, Vincenzo Graziano2, Laura Iezzi1, Patrizia Vici3, Maddalena Barba3, Laura Pizzuti3, Giuseppe Cicero4, Eriseld Krasniqi3, Marco Mazzotta3, Daniele Marinelli5, Antonella Amodio3, Clara Natoli1, Nicola Tinari6

1Department of Innovative Technologies in Medicine & Dentistry, and Center for Advanced Studies and Technology (CAST), G. D’Annunzio University, Chieti, Italy
2Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
3Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy
4Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
5Department of Clinical and Molecular Medicine, Oncology Unit, Sant’Andrea Hospital, Sapienza University, Rome, Italy
6Department of Medical, Oral and Biotechnological Sciences, and Center for Advanced Studies and Technology (CAST), G. D’Annunzio University, Chieti, Italy

*Correspondence: email: grassadonia@unich.it, Tel. +39 0871 3556732, Fax +39 0871 3556707

Abstract: Neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models were used for statistical analyses. Patients with pre-treatment NLRlow showed a significantly shorter DFS (HR 6.97, 95% CI 1.65-10.55, p= 0.002) and OS (HR 7.79, 95% CI 1.25-15.07, p= 0.021) compared to those with NLRhigh. Non-ductal histology, luminal B subtype, and post-treatment Ki67≥ 14% were also associated with worse DFS (p= 0.016, p= 0.002, and p= 0.001, respectively). In multivariate analysis, luminal B subtype, post-treatment Ki67≥ 14%, and NLRlow remained independent prognostic factors for DFS, while only post-treatment Ki67≥ 14% and NLRlow affected OS. The present study provides evidence that pre-treatment NLRlow helps identify women at higher risk of recurrence and death among patients affected by luminal breast cancer treated with NACT.

Keywords: luminal breast cancer; neoadjuvant therapy; neutrophil to lymphocyte ratio (NLR); platelet to lymphocyte ratio (PLR); predictive/prognostic biomarkers.

1. Introduction

Breast cancer is the second cause of cancer death in women in industrialized countries, despite early diagnoses and therapeutic advances have considerably reduced mortality [1]. Neoadjuvant chemotherapy (NACT) is the standard of treatment in locally advanced breast cancer, but in recent years it has been widely used in operable tumors not only to allow breast-conserving surgery (BCS), but also to test in vivo tumor responsiveness to chemotherapy. This latter aspect is particularly important for triple-negative (TN) or human epidermal growth factor receptor 2 (HER2)-positive breast cancer, since patients who do not achieve pathological complete response (pCR) following NACT have a dismal prognosis [2,3]. In these cases, further adjuvant chemotherapy can significantly improve long-term outcome [4–6].
This latter strategy is not applicable in patients affected by luminal A or luminal B-HER2-negative breast cancer (herein referred to as luminal). Indeed, luminal subtypes achieve pCR from NACT infrequently. Still, luminal breast cancers generally maintain a favorable prognosis even in the presence of residual disease [7–10]. Nonetheless, 6-8% of these patients experience relapse within 5 years from diagnosis and dies due to the disease [11]. Thus, the identification of predictive and prognostic factors in patients with luminal breast cancer candidates to NACT is needed. This would help select those patients at higher risk of recurrence who may benefit from further treatment.

Neutrophil-to-Lymphocyte Ratio (NLR) is a peripheral marker of inflammation extensively studied in breast cancer as potential predictor of response to chemotherapy and long-term outcome. Unfortunately, the evidence emerging from the studies carried out this far is inconsistent. Indeed, some studies reported an overall worse prognosis for patients with high NLR [12], while others found no evidence in support of the association of interest [13,14], or even opposite results [15].

In the study herein presented, we retrospectively investigated the prognostic impact of pre-treatment NLR in a cohort of 168 patients with luminal breast cancer who received NACT as primary treatment.

2. Patients and Methods

2.1. Patients

Patients with early or locally advanced luminal breast cancer who received NACT between January 2004 and December 2019 at the Medical Oncology Units of the “S.S. Annunziata” Hospital of Chieti and at the “G. Bernabeo” Hospital of Ortona were consecutively screened for participation in this study. All conditions that could have affected absolute neutrophil or lymphocyte count were carefully evaluated. Specifically, patients with autoimmune diseases or infections, as well as those under steroidal, NSAIDs or antibiotic therapy were excluded from the study.

All breast cancer diagnoses were histologically-confirmed. Following NACT, mostly based on the standard regimens containing anthracycline and/or taxanes, all patients underwent surgical procedures as clinically indicated: mastectomy or breast-conserving surgery (BCS) and axillary lymph node dissection or sentinel lymph node biopsy. Adjuvant radiotherapy was administered to patients with BCS as well as to patients who had undergone mastectomy but had stage cT3, cN2 or cN3 at diagnosis or stage pN2 after surgery. All patients received adjuvant hormonal therapy according to current recommendations. The follow-up contacts were carried out at 6-month intervals over the first 5 years and at 12-month intervals thereafter.

Clinical and pathological tumor staging were defined according to the 8th edition of the American Joint Committee Cancer Staging Manual. This study adheres to the RE-MARK guidelines [16].

2.2. Pathological Assessments

All breast cancer biopsies and surgical specimens were processed for immunohistochemistry (IHC) assessment. Tumors were considered estrogen receptor (ER) or progesterone receptor (PR) positive when receptor staining was expressed in at least 10% of cells [17]. Ki-67 was detected by MIB-1 antibody [18] and a cut-off of 14% was set to discriminate between luminal A (< 14%) and luminal B (≥ 14%) tumors [19]. The nuclear grade was assessed according to the Nottingham grading system [20]. Human epidermal growth factor receptor 2 (HER2) positivity was defined according to the ASCO/CaP guidelines, i.e., a score 3+ in ICH by HercepTest™ (Dako, Milan, Italy) and/or amplification of the inherent gene by FISH or SISH [21]. Only patients diagnosed with ER and/or PR positive and HER2 negative tumors were included in this study.

Pathological complete response (pCR) was defined as the absence of invasive breast cancer in the breast and axillary lymph nodes in the surgical specimen after NACT (ypT0/ypTis, ypN0). Noninvasive breast residuals (carcinoma-in-situ) were allowed.

2.3. Blood Samples and Data Collection
Peripheral complete blood count was performed at baseline, i.e. immediately before starting NACT. Neutrophil to Lymphocyte Ratio was provided by the ratio between the absolute count of neutrophils and the absolute count of lymphocytes. All blood cell assessments were centrally performed at our institutional laboratory according to previously established standardized operative procedures.

Data concerning the clinical and pathological features of all patients, along with the type of treatment administered and long-term outcome, were retrospectively collected and entered into an anonymized dedicated database.

2.4. Study Endpoint

The main objective of the study was to verify the possible prognostic value of NLR in reference to disease free survival (DFS) and overall survival (OS).

2.5. Statistical Analysis

The cut-off points for NLR was calculated by the Receiver Operating Characteristic (ROC) curve for the prediction of distant metastasis. The identified cut-off values split our population into NLR_high and NLR_low. The relationships between NLR and key clinical-pathological characteristics were evaluated by Pearson’s χ².

The Kaplan-Meier method was used to calculate the 10-year rates of DFS and OS in the different patients’ subgroups. The follow-up for OS was defined as the time interval between diagnosis of breast cancer and death, while DFS was intended as the interval between diagnosis and the first appearance of metastatic disease. In patients in whom none of these events occurred, the observational time interval was censored at the last follow-up visit. Differences between curves were evaluated using the Log-rank test. Multivariate analyses were performed using the Cox proportional hazards model according to the backward fitting procedure. Variables with a p< 0.10 at univariate analysis were entered in the model. A p value of 0.05 or less was considered statistically significant. All statistical analyses were performed using SPSS® software 11.0 (SPSS Inc, Chicago, IL, USA).

3. Results

3.1. Patient and Tumor Characteristics

We identified 168 patients with luminal breast cancer who had received NACT and with a pre-treatment complete blood cell count reported in our clinical records. Baseline and post-treatment characteristics, overall and across subgroups defined upon NLR cut-off value, are showed in Table 1 and 2, respectively.
## Pre-treatment characteristics of the study patients for the overall cohort and by NLR.

| Variable                    | N (%) (N = 168) | NLR Low (%) (N = 92) | NLR High (%) (N = 76) | p value |
|-----------------------------|-----------------|----------------------|-----------------------|---------|
| Median age, ys (range)      |                 |                      |                       |         |
| Age (ys)                    |                 |                      |                       |         |
| ≤ 50                        | 87 (51.8)       | 41 (44.6)            | 46 (60.5)             | 0.057   |
| > 50                        | 81 (49.2)       | 51 (55.4)            | 30 (39.5)             |         |
| **Histologic type**         |                 |                      |                       | 0.012   |
| Ductal                      | 108 (64.3)      | 53 (57.6)            | 55 (72.4)             |         |
| Lobular                     | 24 (14.9)       | 14 (15.2)            | 10 (13.2)             |         |
| Ductal/lobular              | 28 (16.7)       | 17 (18.5)            | 11 (14.5)             |         |
| Others                      | 8 (4.10)        | 8 (8.70)             | 0 (0.00)              |         |
| **Grade**                   |                 |                      |                       | 0.303   |
| G1                          | 82 (48.8)       | 47 (51.1)            | 35 (46.1)             |         |
| G2                          | 62 (36.9)       | 30 (32.6)            | 32 (42.1)             |         |
| G3                          | 4 (2.40)        | 3 (3.30)             | 1 (1.30)              |         |
| Unknown*                    | 20 (11.9)       | 12 (13.0)            | 8 (10.5)              |         |
| **Clinical T**              |                 |                      |                       | 0.087   |
| cT1                         | 14 (8.30)       | 5 (5.40)             | 9 (11.8)              |         |
| cT2                         | 122 (72.6)      | 72 (78.3)            | 50 (65.8)             |         |
| cT3                         | 26 (15.5)       | 13 (14.1)            | 13 (17.1)             |         |
| cT4                         | 6 (3.60)        | 2 (2.20)             | 4 (5.30)              |         |
| **Molecular subtype**       |                 |                      |                       | 0.171   |
| Luminal A                   | 130 (77.4)      | 67 (72.8)            | 63 (82.9)             |         |
| Luminal B/HER2              | 38 (22.6)       | 25 (27.2)            | 13 (17.1)             |         |
| **Type of NACT**            |                 |                      |                       | 0.201   |
| EC                          | 25 (14.9)       | 12 (13.0)            | 13 (17.1)             |         |
| EC-T                        | 137 (81.5)      | 75 (81.5)            | 62 (81.6)             |         |
| Others                      | 6 (3.60)        | 5 (5.50)             | 1 (1.30)              |         |
| **No of NACT cycles**       |                 |                      |                       | 1.000   |
| ≤ 4                         | 21 (12.5)       | 11 (12.0)            | 10 (13.2)             |         |
| > 4                         | 147 (87.5)      | 81 (88.0)            | 66 (86.8)             |         |

*Unknown cases were not included in the analysis. NACT, neoadjuvant chemotherapy; EC, epirubicin and cyclophosphamide; T, taxane.
Table 2. Post-treatment characteristics of the study patients for the overall cohort and by NLR.

| Variable                        | n (%) (N = 168) | NLR Low (%) (N = 92) | NLR High (%) (N = 76) | p value |
|---------------------------------|-----------------|----------------------|-----------------------|---------|
| **Type of surgery**             |                 |                      |                       |         |
| BCS                             | 99 (58.9)       | 57 (62.0)            | 42 (55.3)             | 0.519   |
| Mastectomy                      | 69 (41.1)       | 35 (38.0)            | 34 (44.7)             |         |
| **pCR**                         |                 |                      |                       |         |
| Yes                             | 16 (9.50)       | 9 (9.80)             | 7 (9.20)              | 0.890   |
| No                              | 152 (90.5)      | 83 (90.2)            | 69 (90.8)             |         |
| **Ki67 in Residual Tumor**      |                 |                      |                       |         |
| < 14%                           | 140 (83.4)      | 77 (91.6)            | 63 (92.6)             | 0.999   |
| ≥ 14%                           | 12 (7.10)       | 7 (8.40)             | 5 (7.40)              |         |
| Not determinable                | 16 (9.50)       |                      |                       |         |
| **Size of Residual tumor**      |                 |                      |                       |         |
| ≤ 2                             | 111 (66.1)      | 59 (64.1)            | 52 (68.4)             | 0.674   |
| > 2                             | 57 (33.9)       | 33 (35.9)            | 24 (31.6)             |         |
| **No. of metastatic nodes**     |                 |                      |                       |         |
| ≤ 3                             | 127 (75.6)      | 74 (80.4)            | 53 (69.7)             | 0.154   |
| > 3                             | 41 (24.4)       | 18 (19.6)            | 23 (30.3)             |         |
| **Stage**                       |                 |                      |                       |         |
| 0-I                             | 47 (28.0)       | 25 (27.2)            | 22 (28.9)             | 0.472   |
| II                              | 75 (44.6)       | 46 (50.0)            | 29 (38.2)             |         |
| III                             | 46 (27.4)       | 21 (22.8)            | 25 (32.9)             |         |

BCS, breast conserving surgery; pCR, pathological complete response
Median age at diagnosis was 50 years (range 26–74). Prevalent histology was invasive ductal carcinoma (64.3%), but a relevant number of cases included invasive lobular carcinoma (14.9%) and mixed (ductal/lobular) invasive carcinoma (16.7%). Tumor size at diagnosis was > 2 cm (cT2) in the majority of cases (72.6%) and only a few, 2.4% of tumors, were high grade (G3). Based on the Ki67 proliferation index, more than three-quarters of patients (77.4%) had a luminal A tumor subtype, while 22.6% were luminal B-HER2-negative breast cancers. One hundred and thirty-seven patients (81.5%) were treated with a classical anthracycline- and taxane-based sequential chemotherapy, and most patients (87.5%) received at least 4 cycles of chemotherapy.

After NACT, 99 patients (58.9%) underwent a conservative surgical approach, while the remaining 69 (41.1%) were treated by mastectomy (Table 2). Only 16 (9.5%) patients obtained a pCR (10 luminal B and 6 luminal A). The post-treatment Ki67 index in the 152 cases with residual tumor was ≥ 14% in 12 (8.4%) patients as a result of a change from luminal B to luminal A in 19 patients (50% of 38 initially luminal B) by effect of NACT, and the conversion of 3 luminal A to Luminal B. Residual disease in breast was < 2 cm (ypT0 or ypT1) in 111 (66.1%) patients, and 127 (75.6%) had < 3 positive axillary lymph nodes (ypN0 or ypN1). Post-surgery stage was 0 or I in 47 (28.0%) patients.

3.2. Relationship between Clinical-Pathological Characteristics and NLR

In our population, the median value of neutrophils was 3,820/µl (range 1,310–8,830), while that of lymphocytes was 1,920/µl (range 700–6,020). No patient had neutropenia (<1,000/µl) and only 3 patients had lymphocytosis (>4,000/µl).

According to the ROC analysis, the best cut-off values of NLR to identify patients at higher risk of recurrence was < 2.12 (AUC 0.645, 95% CI 0.57–0.72, p= 0.021). This cut-off had a sensitivity of 88.9% and a specificity of 49.3%. The NLR distribution according to basal and post-treatment clinical-pathological characteristics of patients is reported in Table 1 and 2, respectively.

Compared to ductal invasive carcinoma, non-ductal (lobular or mixed) histology was significantly associated with NLR < 2.12 (NLRlow) (p= 0.012). None of the other variables analyzed was significantly associated with NLR. In more detail, no association was observed with pCR.

3.3. Long-Term Outcome

After a median follow-up of 7.98 years (range 1.05–15.25), 18 (10.7%) patients developed distant metastases (10 liver and/or lung, 5 bone only, and 3 brain) and 10 (6.0%) patients had died.

Results of univariate analysis of clinical-pathological characteristics associated with DFS and OS, including NLR, are shown in Table 3.
Table 3. Univariate analysis of clinical-pathological factors predictive of 10-yr DFS and OS.

| Variable                      | N   | DFS 10-yr (%) | HR (95% CI) | p-value | OS 10-yr (%) | HR (95% CI) | p-value |
|-------------------------------|-----|---------------|-------------|---------|-------------|-------------|---------|
| **Age at diagnosis (yr)**     |     |               |             |         |             |             |         |
| ≤ 50                          | 87  | 89.1          | 1.00        |         | 92.0        | 1.00        |         |
| > 50                          | 81  | 79.9          | 0.55 (0.22-1.4) | 0.213  | 90.9        | 0.57 (0.16-1.98) | 0.376  |
| **Histological Type**         |     |               |             |         |             |             |         |
| Ductal                        | 108 | 90.8          | 1.00        |         | 96.5        | 1.00        |         |
| Lobular or mixed              | 52  | 76.1          | 3.12 (1.24-8.28) | 0.016  | 84.6        | 3.24 (0.91-11.38) | 0.069  |
| **Molecular subtype**         |     |               |             |         |             |             |         |
| Luminal A                     | 130 | 88.8          | 1.00        |         | 92.5        | 1.00        |         |
| Luminal B/HER2                | 38  | 63.4          | 3.81 (2.04-29.12) | 0.002  | 89.9        | 2.87 (0.69-27.33) | 0.118  |
| **Grade**                     |     |               |             |         |             |             |         |
| G1                            | 80  | 81.2          | 1.00        |         | 91.8        | 1.00        |         |
| G2-G3                         | 66  | 92.1          | 1.50 (0.51-4.25) | 0.482  | 95.8        | 1.55 (0.33-7.17) | 0.590  |
| **Type of surgery**           |     |               |             |         |             |             |         |
| BCS                           | 99  | 88.9          | 1.00        |         | 83.6        | 1.00        |         |
| Mastectomy                    | 69  | 78.6          | 2.43 (0.96-6.44) | 0.058  | 97.0        | 3.33 (0.94-11.8) | 0.063  |
| **pCR**                       |     |               |             |         |             |             |         |
| Yes                           | 16  | 90.0          | 1.00        |         | 90.0        | 1.00        |         |
| No                            | 152 | 84.2          | 2.33 (0.45-7.66) | 0.396  | 91.8        | 1.10 (0.15-8.16) | 0.930  |
| **Ki67 in residual tumor**    |     |               |             |         |             |             |         |
| < 14%                         | 140 | 86.1          | 1.00        |         | 92.5        | 1.00        |         |
| ≥ 14%                         | 12  | 64.0          | 7.13 (5.26-100) | 0.001  | 72.0        | 31.0 (8.41-100) | 0.002  |
| **Size of residual tumor**    |     |               |             |         |             |             |         |
| ≤ 2 cm                        | 111 | 87.8          | 1.00        |         | 92.0        | 1.00        |         |
| >2 cm                         | 57  | 78.5          | 2.03 (0.81-5.77) | 0.125  | 90.4        | 1.29 (0.35-4.85) | 0.691  |
| **No. of metastatic nodes**   |     |               |             |         |             |             |         |
| ≤ 3                           | 127 | 85.0          | 1.00        |         | 91.8        | 1.00        |         |
| >3                            | 41  | 84.4          | 1.48 (0.49-4.86) | 0.453  | 90.3        | 1.51 (0.35-7.19) | 0.545  |
| **Stage**                     |     |               |             |         |             |             |         |
| 0-I                           | 47  | 93.6          | 1.00        |         | 93.6        | 1.00        |         |
| II-III                        | 121 | 81.0          | 2.52 (0.93-6.87) | 0.070  | 90.5        | 1.52 (0.38-6.12) | 0.347  |
| **NLR**                       |     |               |             |         |             |             |         |
| High                          | 76  | 98.3          | 1.00        |         | 97.9        | 1.00        |         |
| Low                           | 92  | 74.0          | 6.97 (1.65-10.55) | 0.002  | 86.2        | 7.79 (1.25-15.07) | 0.021  |

* Unadjusted Kaplan-Meier estimates.
Non-ductal histology, luminal B subtype, and Ki67 ≥ 14% in residual tumor after NAC were the factors associated with a significantly worse DFS. In Kaplan–Meier analysis, the estimated cumulative 10-year DFS rates were 76.1% for non-ductal tumors compared to 90.8% for their ductal counterpart (HR 3.12, 95% CI 1.24–8.28, p = 0.016) (Figure 1 a); 63.4% for luminal B compared to 88.8% for luminal A (HR 3.81, 95% CI 2.04–29.12, p = 0.002) (Figure 1 b); and 64% for Ki67 ≥ 14% compared to 86.1% for Ki67 < 14% (HR 7.13, 95% CI 5.26–100, p = 0.001) (Figure 2 a). A trend towards a shorter DFS was observed in patients who underwent mastectomy, compared to those treated with BCS (p = 0.058), and in patients with pathological stage II or III after NACT, compared to those with stage 0-I (p = 0.070).

Ki67 ≥ 14% in residual tumor was also significantly associated with lower 10-year OS rates (64.1% vs 86%, p = 0.002) (Figure 2 b). A trend towards worse OS was observed for non-ductal histology (p = 0.069) as well as for mastectomy (p = 0.063), while luminal B subtype did not affect OS significantly (p = 0.118).

NLRlow resulted significantly associated with higher risk of disease recurrence and death, showing a 10-year DFS rate of 74.0% compared to 98.3% for NLRhigh (HR 6.97, 95% CI 1.65–10.55, p = 0.002) (Figure 3 a) and a 10-year OS rate of 86.2% compared to 97.9% for NLRhigh (HR 7.79, 95% CI 1.25–15.07, p = 0.021) (Figure 3 b).
In multivariate analysis, luminal B subtype (p=0.049), Ki67 $\geq 14\%$ in residual tumor (p=0.024), and NLR$^{\text{low}}$ (p=0.033) were independent prognostic factors for DFS, while only Ki67 $\geq 14\%$ (p=0.024) and NLR$^{\text{low}}$ (p=0.042) maintained significance for OS (Table 4).

**Table 4.** Multivariate analysis of factors influencing DFS and OS.

|                          | Disease Free Survival | Overall Survival |
|--------------------------|-----------------------|------------------|
|                          | HR (95% CI)           | p-value          |
| **Histological type**    |                       |                  |
| Non-ductal vs Ductal     | 1.90 (0.67-5.44)      | 0.228            |
| **Molecular subtype**    |                       |                  |
| Luminal B vs Luminal A   | 3.00 (1.00-9.84)      | **0.049**        |
| **Type of surgery**      |                       |                  |
| Mastectomy vs BCS        | 1.96 (0.72-5.38)      | 0.188            |
| **Ki67 in residual tumor** |                      |                  |
| $\geq 14\%$ vs $< 14\%$ | 6.32 (1.27-31.29)     | **0.024**        |
| **Stage**                |                       |                  |
| II-III vs I              | 4.52 (0.91-22.42)     | 0.064            |
| **Peripheral markers of inflammation** | |                  |
| NLR$^{\text{low}}$ vs NLR$^{\text{high}}$ | 5.36 (1.14-25.17) | **0.033**        |

**Figure 3.** Cumulative disease-free survival (a) and overall survival (b) stratified by NLR

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 May 2021

doi:10.20944/preprints202105.0144.v1
4. Discussion

In this retrospective study we examined the prognostic role of pre-treatment NLR in a cohort of 168 early or locally advanced breast cancer patients with luminal tumor treated with NACT. We found that NLR\textsuperscript{low} was associated with adverse long-term outcome in reference to DFS and OS.

Furthermore, we found that DFS was affected by non-ductal (lobular or mixed) histology, by luminal B subtype, and by Ki67 ≥ 14% in residual tumor after NACT. These results are in line with expectations. In fact, a non-ductal histology, in particular lobular invasive carcinoma, predicts a poor response to NACT\cite{22–24} and a shorter survival\cite{25} compared to ductal tumors. Similarly, luminal B breast cancer, defined by Ki67 ≥ 14%, is a well recognized subtype with worse prognosis compared to luminal A\cite{26,27}, and patients with high post-treatment Ki67 levels have been showed to be at higher risk of recurrence and death compared with patients with low Ki67 levels\cite{28}.

In multivariate analysis, non-ductal histology was no longer significant, while the prognostic role of NLR\textsuperscript{low}, luminal B, and post-treatment Ki67 ≥ 14% was maintained. This latter result can be explained by the significant correlation of non-ductal histology with NLR\textsuperscript{low} (p= 0.012). Consistently with previous studies\cite{9,29}, a trend towards shorter DFS was observed for patients who underwent mastectomy (vs BCS) and for those with more advanced stage of disease after surgery (stage II-III vs stage 0-I), parameters directly linked to lack of response to NACT.

NLR\textsuperscript{low} and post-treatment Ki67 ≥ 14% were also factors that negatively influenced OS (p= 0.01 and p= 0.002, respectively), along with the necessity to perform mastectomy after NACT and non-ductal histology, characteristics that in our population were associated with a trend towards significance (p= 0.068 and p =0.069, respectively). In multivariate analysis, only NLR\textsuperscript{low} and post-treatment Ki67 ≥ 14% were significantly associated with shorter OS.

To our knowledge, this is the first study showing an adverse prognostic effect of NLR\textsuperscript{low} in a subgroup of breast cancer patients. NLR has been widely studied as a marker of the host systemic inflammatory response during cancer development and progression and its elevation is associated with poor prognosis in several cancers, including breast cancer\cite{30,31}. Its prognostic role has been well defined in more advanced stage of disease where the boosted inflammatory response, usually revealed by increased level of C-reactive protein and hypoalbuminemia, can promote tumor growth through the production of cytokines and growth factors\cite{32,33}.

In breast cancer, several studies have investigated NLR as a prognostic factor in the adjuvant setting. Most of them did not differentiate among breast cancer subtypes and a general correlation of NLR\textsuperscript{high} with worse survival has been reported\cite{34}. Interestingly, a recent meta-analysis analyzed NLR in the different breast cancer subtypes and found an association between NLR\textsuperscript{high} and OS only for HER2-positive and TN tumors, but not for luminal A or luminal B cancers\cite{35}. This may be indicative of a different biological behavior of these breast cancer subtypes with respect to the systemic inflammatory response.

In breast cancer, several studies have investigated NLR as a prognostic factor in the adjuvant setting. Most of them did not differentiate among breast cancer subtypes and a general correlation of NLR\textsuperscript{high} with worse survival has been reported\cite{34}. Interestingly, a recent meta-analysis analyzed NLR in the different breast cancer subtypes and found an association between NLR\textsuperscript{high} and OS only for HER2-positive and TN tumors, but not for luminal A or luminal B cancers\cite{35}. This may be indicative of a different biological behavior of these breast cancer subtypes with respect to the systemic inflammatory response.

Few studies have investigated pre-treatment NLR as predictive/prognostic factor in patients treated with NACT. This setting offers the chance to assess the role of NLR in the response to treatment, and, more specifically, its association with pCR. We have previously described higher pCR rates in patients with NLR\textsuperscript{low} compared to those with NLR\textsuperscript{high} in a population including all breast cancer subtypes\cite{36}. Similarly, a further study showed an increased pCR rate in the group of patients with NLR\textsuperscript{low}, but exclusively in TN tumor\cite{37}. However, other studies failed to demonstrate any association between NLR and pCR\cite{38,39}.

Inconsistent results have been reported also for long-term outcome after NACT. Some studies showed an association of NLR\textsuperscript{high} with shorter survival\cite{40,41}, while others found no prognostic correlations\cite{38,39,42}. Among these studies, which included all breast cancer molecular subtypes, only one single study performed a subgroup analysis.
showing that NLR^{high} was associated with shorter DFS and OS in patients with TN tumor who achieved pCR, but not in luminal subtypes [42]. Conversely, Koh et al. reported that NLR^{high} was an independent prognostic factor in a group of 167 patients with luminal HER2-negative breast cancer [43]. A recently published study on a large cohort of breast cancer patients (1,519 cases) treated with NACT and stratified by molecular subtype (261 TN, 377 HER2-positive, and 881 luminal-HER2-negative) found that pretreatment NLR^{high} was independently associated with a worse OS in TN and HER2-positive breast cancer, but no association was observed in luminal tumors.

Taken together, with the exception of the Koh’s study, the prognostic value of NLR in early breast cancer seems to be driven by the molecular subtype, although the number of studies addressing this issue is currently limited. The available evidence points to an adverse prognostic effect of NLR^{high} limitedly to the subgroups of patients with TN or HER2-positive tumors.

In our study we focused on luminal subtype and found the opposite of what has been reported for TN or HER2-positive tumors, i.e., NLR^{low}, rather than NLR^{high}, was associated with shorter survival. In the following lines, we attempt to provide explanations for this apparently paradoxical result.

It is noteworthy that breast cancer subtypes greatly differ not only by ER, PR or HER2 expression, but also by tumor mutation burden and tumor microenvironment. The tumor mutation burden reflects the amount of tumor somatic mutations and the higher this level, the higher the chances that new antigens are recognized as non-self and trigger an immune response against cancer [44,45]. Breast cancer has an intermediate level of tumor mutation burden compared to other types of cancers [46], which is higher in TN and HER2-positive tumor compared to luminal tumor [47]. In addition, tumor microenvironment is now recognized as a pivotal regulator of immune response against cancer [48]. In particular, tumor-infiltrating lymphocytes (TILs) are more frequently observed in TN or HER2-positive breast cancer [49], and higher levels in tumor stroma are associated with higher rate of pCR [50] and better prognosis [51] in these subtypes. Of note, it has been reported that in luminal tumors the degree of TILs has an opposite prognostic meaning compared to TN or HER2-positive breast cancer, i.e., higher levels of TILs are associated with poorer prognosis [51]. At the time of this manuscript writing, the underlining mechanisms to this finding are not fully understood. It is conceivable that the lymphocyte infiltrate of HER2-positive or TN subtypes is different from that of luminal tumor, or that hormones modulate negatively the tumor-associated immunological cells. Another possibility is that immune response may affect response to hormone therapy [52,53].

The contradictory results of TILs across different breast cancer subtypes resemble what we have observed for NLR in the present study. Differently from HER2-positive or TN subtypes, in luminal breast cancer NLR^{low} is an adverse prognostic factor for survival, suggesting a different biology of this subtype. Interestingly, it has been reported that NLR might reflect the immune cell infiltrate of tumor stroma and inversely correlate with TILs, i.e. the higher the TIL level, the lower NLR [54–57]. Thus, we could speculate that in luminal tumors higher TILs are associated with lower NLR and this condition negatively affects immune response and patients’ prognosis. Further studies on the association between TILs and NLR in luminal breast cancer and on the characterization of the immune cell infiltrate in tumor microenvironment are needed to clarify this assumption. Different T lymphocyte populations, including CD4+, CD8+, and Treg, may orchestrate the balance between pro-inflammatory and pro-immunogenic response, and this may eventually influence clinical outcome.

The finding of our study should be interpreted with caution due to its retrospective design and the relatively limited sample size. In addition, we did not have information about basal level of LDH, C-reactive protein, and albumin, parameters that could be helpful on the interpretation of NLR levels in the context of the inflammatory status of the patients. However, the present study provides insights into the possible role of NLR in breast cancer as an indicator of activity of the immune system against cancer, rather than a mere marker of host’s systemic inflammation.
5. Conclusions

We suggest that NLR\textsubscript{low} may be an indicator of inadequate anti-cancer immune response and, therefore, of dismal long-term prognosis in patients with luminal breast cancer treated with NACT.

Author Contributions: Conceptualization, Antonino Grassadonia and Nicola Tinari; Data curation, Laura Iezzi and Eriseld Krasniqi; Formal analysis, Giuseppe Cicero and Nicola Tinari; Methodology, Maddalena Barba and Antonella Amodio; Supervision, Patrizia Vici and Clara Natoli; Validation, Marco Mazzotta and Daniele Marinelli; Writing – original draft, Antonino Grassadonia and Vincenzo Graziano; Writing – review & editing, Maddalena Barba and Laura Pizzuti.

Funding: This research received no external funding

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Chieti-Pescara on 17th May 2018 (IRB No. 10 2018-05-17).

Informed Consent Statement: Informed consent was waived because of the retrospective nature of the study and the analysis used anonymous clinical data.

Acknowledgments: This work was supported by the Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA. Cancer J. Clin. 2019, 69, 7–34, doi:10.3322/caac.21551.
2. von Minckwitz, G.; Untch, M.; Blohmer, J.-U.; Costa, S.D.; Eidtmann, H.; Fasching, P.A.; Gerber, B.; Eiermann, W.; Hilfrich, J.; Huober, J.; et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012, 30, 1796–1804, doi:10.1200/JCO.2011.38.8595.
3. Untch, M.; Fasching, P.A.; Konecny, G.E.; Hasmüller, S.; Lebeau, A.; Kreienberg, R.; Camara, O.; Müller, V.; du Bois, A.; Kühn, T.; et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29, 3351–3357, doi:10.1200/JCO.2010.31.4930.
4. von Minckwitz, G.; Huang, C.-S.; Mano, M.S.; Loibl, S.; Mamounas, E.P.; Untch, M.; Wolmark, N.; Rastogi, P.; Schneweiss, A.; Redondo, A.; et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med. 2019, 380, 617–628, doi:10.1056/NEJMoa1814017.
5. Masuda, N.; Lee, S.-J.; Ohtani, S.; Im, Y.-H.; Lee, E.-S.; Yokota, I.; Kuroi, K.; Im, S.-A.; Park, B.-W.; Kim, S.-B.; et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N. Engl. J. Med. 2017, 376, 2147–2159, doi:10.1056/NEJMoa1612645.
6. Wang, X.L.; Wang, S.-S.; Huang, H.; Cai, L.; Peng, R.-J.; Zhao, L.; Lin, Y.; Zeng, J.; Zhang, L.-H.; Ke, Y.-L.; et al. Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001). J. Clin. Oncol. 2020, 38, 507, doi:10.1200/JCO.2020.38.15_suppl.507.
7. Wang-Lopez, Q.; Chalabi, N.; Abrial, C.; Radosevic-Robin, N.; Durando, X.; Mouret-Reynier, M.-A.; Benmammar, K.-E.; Kullab, S.; Bahadoor, M.; Chollet, P.; et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit. Rev. Oncol. Hematol. 2015, 95, 88–104, doi:10.1016/j.critrevonc.2015.02.011.
8. Cortazar, P.; Zhang, L.; Untch, M.; Mehta, K.; Costantino, J.P.; Wolmark, N.; Bonnefoi, H.; Cameron, D.; Gianni,
9. Angelucci, D.; Tinari, N.; Grassadonia, A.; Cianchetti, E.; Ausili-Cefaro, G.; Iezzi, L.; Zilli, M.; Grossi, S.; Ursini, L.A.; Scognamiglio, M.T.; et al. Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. J. Cancer Res. Clin. Oncol. 2013, 139, 269–280, doi:10.1007/s00432-012-1325-9.

10. Grassadonia, A.; Di Nicola, M.; Grossi, S.; Noccioli, P.; Tavoletta, S.; Politi, R.; Angelucci, D.; Marinelli, C.; Zilli, M.; Ausili Cefaro, G.; et al. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Ann. Surg. Oncol. 2014, 21, 1575–1582, doi:10.1245/s10434-014-3535-7.

11. DeSantis, C.E.; Ma, J.; Gaudet, M.M.; Newman, L.A.; Miller, K.D.; Goding Sauer, A.; Jemal, A.; Siegel, R.L. Breast cancer statistics, 2019. CA. Cancer J. Clin. 2019, 69, 438–451, doi:10.3322/caac.21583.

12. Guo, W.; Lu, X.; Liu, Q.; Zhang, T.; Li, P.; Qiao, W.; Deng, M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Med. 2019, 8, 4135–4148, doi:10.1002/cam4.2281.

13. Azab, B.; Shah, N.; Radbel, J.; Tan, P.; Bhatt, V.; Vonfroliol, S.; Habeshy, A.; Picon, A.; Bloom, S. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med. Oncol. 2013, 30, 432, doi:10.1007/s12032-012-0432-4.

14. Hu, Y.; Wang, S.; Ding, N.; Li, N.; Huang, J.; Xiao, Z. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio As a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2(-)) Breast Cancer. Clin. Breast Cancer 2020, doi:10.1016/j.jbcb.2020.01.008.

15. Gündüz, S.; Göksu, S.S.; Arslan, D.; Tatli, A.M.; Uysal, M.; Gündüz, U.R.; Sevinç, M.M.; Coşkun, H.S.; Bozcuk, H.; Mutlu, H.; et al. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Mol. Clin. Oncol. 2015, 3, 1109–1112, doi:10.3892/mco.2015.610.

16. Sauerbrei, W.; Taube, S.E.; McShane, L.M.; Cavenagh, M.M.; Altman, D.G. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J. Natl. Cancer Inst. 2018, 110, 803–811, doi:10.1093/jnci/djy088.

17. Hammond, M.E.H.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 2010, 134, e48-72, doi:10.1043/1543-2165-134.7.e48.

18. Dowsett, M.; Nielsen, T.O.; A’Hern, R.; Bartlett, J.; Coombes, R.C.; Cuzick, J.; Ellis, M.; Henry, N.L.; Hugh, J.C.; Lively, T.; et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl. Cancer Inst. 2011, 103, 1656–1664, doi:10.1093/jnci/djr393.

19. Goldhirsh, A.; Wood, W.C.; Coates, A.S.; Gelber, R.D.; Thürlimann, B.; Senn, H.-J. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2011, 22, 1736–1747.

20. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19, 403–410, doi:10.1111/j.1365-2559.1991.tb00229.x.

21. Wolff, A.C.; Hammond, M.E.H.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.S.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice
22. Skriver, S.K.; Laenholm, A.-V.; Rasmussen, B.B.; Handler, J.; Grundtmann, B.; Tvedskov, T.F.; Christiansen, P.; Knoop, A.S.; Jensen, M.-B.; Ejlersen, B. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol. 2018, 57, 31–37, doi:10.1080/0284186X.2017.1401228.

23. Loibl, S.; Volz, C.; Mau, C.; Blohmer, J.-U.; Costa, S.D.; Eidtmann, H.; Fasching, P.A.; Gerber, B.; Hanusch, C.; Jackisch, C.; et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res. Treat. 2014, 144, 153–162, doi:10.1007/s10549-014-2861-6.

24. Delpech, Y.; Coutant, C.; Hsu, L.; Barranger, E.; Iwamoto, T.; Barcenas, C.H.; Hortobagyi, G.N.; Rouzier, R.; Esteva, F.J.; Pusztai, L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br. J. Cancer 2013, 108, 285–291, doi:10.1038/bjc.2012.557.

25. Adachi, Y.; Ishiguro, J.; Kotani, H.; Hisada, T.; Ichikawa, M.; Gondo, N.; Yoshimura, A.; Kondo, N.; Hattori, M.; Sawaki, M.; et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer 2016, 16, 248, doi:10.1186/s12885-016-2275-4.

26. Sotiriou, C.; Neo, S.-Y.; McShane, L.M.; Korn, E.L.; Long, P.M.; Jazaeri, A.; Martiat, P.; Fox, S.B.; Harris, A.L.; Liu, E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 10393–10398, doi:10.1073/pnas.1732912100.

27. Ades, F.; Zardavas, D.; Bozovic-Spasojevic, I.; Pugliano, L.; Fumagalli, D.; de Azambuja, E.; Viale, G.; Sotiriou, C.; Piccart, M. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 2794–2803, doi:10.1200/JCO.2013.54.1870.

28. von Minckwitz, G.; Schmitt, W.D.; Loibl, S.; Müller, B.M.; Blohmer, J.U.; Sinn, B.V.; Eidtmann, H.; Eiermann, W.; Gerber, B.; Tesch, H.; et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 2013, 19, 4521–4531, doi:10.1158/1078-0432.CCR-12-3628.

29. Symmans, W.F.; Peintinger, F.; Hatzis, C.; Rajan, R.; Kuerer, H.; Valero, V.; Assad, L.; Poniecka, A.; Hennessy, B.; Green, M.; et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25, 4414–4422, doi:10.1200/JCO.2007.10.6823.

30. Templeton, A.J.; McNamara, M.G.; Šeruga, B.; Vera-Badillo, F.E.; Aneja, P.; Ocaña, A.; Leibowitz-Amit, R.; Sonpavde, G.; Knox, J.J.; Tran, B.; et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2014, 106, dju124, doi:10.1093/jnci/dju124.

31. Templeton, A.J.; Ace, O.; McNamara, M.G.; Al-Mubarak, M.; Vera-Badillo, F.E.; Hermans, T.; Seruga, B.; Ocaña, A.; Tannock, I.F.; Amir, E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol. biomarkers Prev. a Publ. Am. Assoc. Cancer Res. cosponsored by Am. Soc. Prev. Oncol. 2014, 23, 1204–1212, doi:10.1158/1055-9965.EPI-14-0146.

32. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991–998, doi:10.1038/ni1102-991.

33. Guthrie, G.J.K.; Charles, K.A.; Roxburgh, C.S.D.; Horgan, P.G.; McMillan, D.C.; Clarke, S.J. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013, 88, 218–230, doi:10.1016/j.critrevonc.2013.03.010.

34. Corbeau, I.; Jacot, W.; Guiu, S. Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. Cancers (Basel). 2020, 12, doi:10.3390/cancers12040958.

35. Wei, B.; Yao, M.; Xing, C.; Wang, W.; Yao, J.; Hong, Y.; Liu, Y.; Fu, P. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco. Targets. Ther. 2016, 9, 5567–5575, doi:10.2147/OTT.S108419.
36. Graziano, V.; Grassadonia, A.; Iezzi, L.; Vici, P.; Pizzuti, L.; Barba, M.; Quinzii, A.; Campese, A.; Di Marino, P.; Peri, M.; et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. *Breast* **2019**, *44*, 33–38, doi:10.1016/j.breast.2018.12.014.

37. Chae, S.; Kang, K.M.; Kim, H.J.; Kang, E.; Park, S.Y.; Kim, J.H.; Kim, S.H.; Kim, S.W.; Kim, E.K. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. *Curr. Oncol.* **2018**, *25*, e113–e119, doi:10.3747/co.25.35888.

38. Suppan, C.; Bjelic-Radisic, V.; La Garde, M.; Groselj-Strele, A.; Eberhard, K.; Samonigg, H.; Loibner, H.; Dandachi, N.; Balic, M. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. *BMC Cancer* **2015**, *15*, 1027, doi:10.1186/s12885-015-2005-3.

39. Losada, B.; Guerra, J.A.; Malón, D.; Jara, C.; Rodriguez, L.; Del Barco, S. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. *Clin. Transl. Oncol.* **2019**, *21*, 855–863, doi:10.1007/s12094-018-1999-9.

40. Chen, Y.; Chen, K.; Xiao, X.; Nie, Y.; Qu, S.; Gong, C.; Su, F.; Song, E. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. *BMC Cancer* **2016**, *16*, 320, doi:10.1186/s12885-016-2352-8.

41. Marin Hernández, C.; Piñero Madrona, A.; Gil Vázquez, P.J.; Galindo Fernández, P.J.; Ruiz Merino, G.; Alonso Romero, J.L.; Parrilla Paricio, P. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. *Clin. Transl. Oncol.* **2018**, *20*, 476–483, doi:10.1007/s12094-017-1732-0.

42. Asano, Y.; Kashiwagi, S.; Onoda, N.; Noda, S.; Kawajiri, H.; Takashima, T.; Ohsawa, M.; Kitagawa, S.; Hirakawa, K. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. *Ann. Surg. Oncol.* **2016**, *23*, 1104–1110, doi:10.1245/s10434-015-4934-0.

43. Koh, Y.W.; Lee, H.J.; Ahn, J.-H.; Lee, J.W.; Gong, G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. *Tumour Biol.* *J. Int. Soc. Oncodevelopmental Biol. Med.* **2014**, *35*, 9823–9830, doi:10.1007/s13277-014-2282-5.

44. Chan, T.A.; Yarchoan, M.; Jaffee, E.; Swanton, C.; Quezada, S.A.; Stenzinger, A.; Peters, S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann. Oncol.* *Off. J. Eur. Soc. Med. Oncol.* **2019**, *30*, 44–56, doi:10.1093/annonc/mdy495.

45. Wang, X.; Li, M. Correlate tumor mutation burden with immune signatures in human cancers. *BMC Immunol.* **2019**, *20*, 4, doi:10.1186/s12865-018-0285-5.

46. Lawrence, M.S.; Stojanov, P.; Polak, P.; Kryukov, G. V.; Cibulskis, K.; Sivachenko, A.; Carter, S.L.; Stewart, C.; Mermel, C.H.; Roberts, S.A.; et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* **2013**, *499*, 214–218, doi:10.1038/nature12213.

47. Angus, L.; Smid, M.; Wilting, S.M.; van Riet, J.; Van Hoeck, A.; Nguyen, L.; Nik-Zainal, S.; Steenbruggen, T.G.; Tjan-Heijnen, V.C.G.; Labots, M.; et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. *Nat. Genet.* **2019**, *51*, 1450–1458, doi:10.1038/s41588-019-0507-7.

48. Annaratone, L.; Cascardi, E.; Vissio, E.; Sarotto, I.; Chmielik, E.; Sapino, A.; Berrino, E.; Marchiò, C. The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. *Pathobiology* **2020**, *87*, 125–142, doi:10.1159/000507055.
49. Wein, L.; Savas, P.; Luen, S.J.; Virassamy, B.; Salgado, R.; Loi, S. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. *Front. Oncol.* 2017, 7, 156, doi:10.3389/fonc.2017.00156.

50. Denkert, C.; von Minckwitz, G.; Brase, J.C.; Sinn, B.V; Gade, S.; Kronenwett, R.; Pfitzner, B.M.; Salat, C.; Loi, S.; Schmitt, W.D.; et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2015, 33, 983–991, doi:10.1200/JCO.2014.58.1967.

51. Denkert, C.; von Minckwitz, G.; Darb-Esfahani, S.; Lederer, B.; Heppner, B.I.; Weber, K.E.; Budczies, J.; Huober, J.; Klauschen, F.; Furlanetto, J.; et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet. Oncol.* 2018, 19, 40–50, doi:10.1016/S1470-2045(17)30904-X.

52. Gao, Q.; Patani, N.; Dunbier, A.K.; Ghazoui, Z.; Zvelebil, M.; Martin, L.-A.; Dowsett, M. Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. *Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res.* 2014, 20, 2485–2494, doi:10.1158/1078-0432.CCR-13-2602.

53. Dunbier, A.K.; Ghazoui, Z.; Anderson, H.; Salter, J.; Nerurkar, A.; Osin, P.; A’hern, R.; Miller, W.R.; Smith, I.E.; Dowsett, M. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. *Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res.* 2013, 19, 2775–2786, doi:10.1158/1078-0432.CCR-12-1000.

54. Lee, J.; Kim, D.-M.; Lee, A. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. *Cancer Res. Treat.* 2019, 51, 649–663, doi:10.4143/crt.2018.270.

55. Tanaka, R.; Kimura, K.; Eguchi, S.; Tauchi, J.; Shibutani, M.; Shinkawa, H.; Ohira, G.O.; Yamazoe, S.; Tanaka, S.; Amano, R.; et al. Preoperative Neutrophil-to-lymphocyte Ratio Predicts Tumor-infiltrating CD8(+) T Cells in Biliary Tract Cancer. *Anticancer Res.* 2020, 40, 2881–2887, doi:10.21873/anticanres.14264.

56. Ha, S.Y.; Choi, S.; Park, S.; Kim, J.M.; Choi, G.-S.; Joh, J.-W.; Park, C.-K. Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma. *Virchows Arch.* 2020, doi:10.1007/s00428-020-02841-5.

57. Han, S.; Liu, Y.; Li, Q.; Li, Z.; Hou, H.; Wu, A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. *BMC Cancer* 2015, 15, 617, doi:10.1186/s12885-015-1629-7.